| abstract |
This invention pertains to the use of an uridine source, preferably uridine monophosphate,for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8μM in a subject in need thereof, comprising administering to said subject a composition comprising 300 –900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes. |